Shots:

• The NMPA has approved Hanbeita for mCRC and unresectable, LA, recurrent or metastatic nsq.NSCLC. The approval helps to improve the accessibility of bevacizumab & offers a high-quality option for patients
• The results showed that Hanbeitai is highly similar to Zercepac & no difference in efficacy & safety was observed. The company also develops serplulimab for NSCLC and has a clinical trials program to test the product in combination with bevacizumab
• Hanbeitai marks 4th Henlius' biosimilar to be approved in China, following Hanlikang (rituximab), Hanquyou (trastuzumab) & Handayuan (adalimumab), while Hanquyou is approved in EU & marketed under brand name Zercepac

Ref: PR Newswire | Image: Henlius